<DOC>
	<DOCNO>NCT01776814</DOCNO>
	<brief_summary>Chronic hepatitis B virus infection important cause morbidity mortality . Tenofovir disoproxil fumarate entecavir license treatment hepatitis B virus infection . In study , investigator try make comparison Entecavir Tenofovir investigate efficacy .</brief_summary>
	<brief_title>Comparison Efficacy Entecavir Tenofovir Monotherapy Treatment Nucleos ( ) Ide-na√Øve Patients With Chronic Hepatitis B Korea</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>18 &lt; Age &lt; 70 HBV DNA &gt; 100,000 copies/mL increase ALT 2 time compare normal range HBsAg ( + ) , HBeAg ( + ) HBV DNA &gt; 10,000 copies/mL increase ALT compare normal range HBsAg ( + ) , HBeAg ( ) With HCV liver disease With kidney disease decompensated liver cirrhosis hepatocellular carcinoma refuse clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Entecair</keyword>
	<keyword>Tenofovir</keyword>
</DOC>